ArticleWorld journal of gastroenterology2005
Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Natural compounds regulate the PI3K/Akt/GSK3β pathway in myocardial ischemia-reperfusion injury.Cell cycle (Georgetown, Tex.) · 2023Article
- Gut microbiome: decision-makers in the microenvironment of colorectal cancer.Frontiers in cellular and infection microbiology · 2023Review
- A novel potential inflammation-nutrition biomarker for predicting lymph node metastasis in clinically node-negative colon cancer.Frontiers in oncology · 2023Article
- CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro.Cancer cell international · 2020Article
- Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways.Bioscience reports · 2020Review
- Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Article
- miR-590-5P inhibits the progression of tongue squamous cell carcinoma by targeting FasL.International journal of clinical and experimental pathology · 2017Article
- Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.International journal of molecular sciences · 2015Article
- Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.International journal of clinical and experimental pathology · 2015Article
- In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.Frontiers in oncology · 2015Article
- Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.World journal of gastroenterology · 2014Review
- Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.World journal of gastroenterology · 2010Article
- Colon cancer and the immune system: the role of tumor invading T cells.World journal of gastroenterology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine the role of Fas/Fas ligand (FasL) in the immune escape of colon cancer cells.
methodsImmunohistochemistry was used to observe the expression of Fas and FasL in the tissues of colon cancer patients. In situ hybridization was used to detect the localization of FasL mRNA expression in cancer tissues. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assay and CD45 staining were performed to detect the apoptosis of tumor-infiltrating lymphocytes (TILs). Co-culture assays of colon cancer cells (SW480) and Jurkat cells (Fas-sensitive cells) were performed to observe the counterattack of colon cancer cells to lymphocytes.
resultsOf 53 cases of colon carcinomas, 23 cases (43.4%) expressed Fas which was significantly lower as compared to the normal colonic mucosa (73.3%, P<0.01), and 45 cases (84.9%) of colon carcinomas expressed FasL, whereas only two cases (3.75%) in normal mucosa expressed FasL. FasL expression in the colon cancer cells was found to be associated with increased cell death of TILs. The apoptotic rate of TIL in the FasL-positive staining regions of tumor cells was significantly higher than that in the FasL-negative staining region (54.84+/-2.79% vs 25.73+/-1.98%, P<0.01). The co-culture of SW480 cells and Jurkat cells confirmed the function of FasL on the SW480 cells. The apoptotic rates of Jurkat cells were found to be related with the amount of SW480 cells.
conclusionColon cancer cells can escape the immune surveillance and killing via decreasing Fas expression, and can counterattack the immune system via increasing FasL expression. Fas/FasL can serve as potential targets for effective antitumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.